ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
48 announcements with these filters
Rubicon Research Ltd has filed its quarterly shareholding pattern as of June 30, 2026, in compliance with SEBI Regulation 31. The report reflects recent ESOP allotment data.
Rubicon Research disclosed a US FDA inspection at its Pithampur facility, yielding 2 procedural observations. The company is confident in resolving them, with no impact on data integrity or operations.
Rubicon Research reports robust Q4 FY26 results with 44% revenue growth and 112% PAT growth. Strategy shifts toward direct Indian market presence via Arinna Lifesciences acquisition.
Rubicon Research delivered a strong Q4 FY26 with 44% revenue growth and 112% profit increase, driven by a robust product pipeline and stable pricing despite outsourcing manufacturing for excess demand.
Rubicon Research recommended a final dividend of ₹1.5 per equity share for FY2026. The record date and AGM schedule will be announced following future board approval.
Rubicon Research Limited filed its Annual Secretarial Compliance Report for the financial year 2026. The report confirms full compliance with SEBI regulations with no fines levied.
Rubicon Research extended the timeline for utilising ₹147.63 Crore in unutilised IPO proceeds until March 2027. This extension provides operational flexibility for strategic investments and debt repayment.
Rubicon Research approved a new Employee Stock Option Scheme 2026 covering 24,84,415 equity shares. The plan aims to incentivize employees across the company and its subsidiaries.
Rubicon Research (Q4 FY26) reported revenue of ₹5,139M (up 43.5% YoY) and PAT of ₹768M (up 111.8% YoY). Strategy focuses on specialty products and US nasal spray market leadership.
Rubicon Research Ltd reported revenue from operations of ₹513.9 Cr (+43.5% YoY) and net profit of ₹76.8 Cr (+112.2% YoY) for Q4 FY26.
Rubicon Research reported audited FY26 results and recommended a ₹1.50 per share dividend. The performance reflects steady growth and continued shareholder returns.
Rubicon Research scheduled a board meeting for May 29, 2026, to approve annual audited financial results. Directors will also consider a dividend recommendation for the fiscal year.
Rubicon Research Limited completed the acquisition of an 85% stake in Arinna Lifesciences Limited on April 30, 2026. Following this transaction, Arinna Lifesciences has become a subsidiary of the company. This move follows the terms of a previously signed Share Purchase Agreement.
Rubicon Research Limited announced the successful conclusion of an unannounced USFDA inspection at its R&D facility in Concord, Ontario, Canada. The inspection, conducted from April 20 to April 24, 2026, concluded without any Form-483 observations being issued. This outcome confirms the company's adherence to high quality and compliance standards.
Rubicon Research Limited received an Income Tax Assessment Order for AY 2023-24 with a demand of ₹17.25 Crore. The demand relates to Arms' Length Pricing adjustments. The company is in the process of filing an appeal and remains confident in its legal position.
Rubicon Research Limited is acquiring an 85% stake in Arinna Lifesciences Limited for approximately ₹175.92 Crore. This acquisition facilitates Rubicon's entry into the Indian CNS formulations market. The transaction values Arinna at an enterprise value of ₹200 Crore and is expected to close within 30 days.
Rubicon Research Limited is acquiring an 85% stake in Arinna Lifesciences Limited for approximately ₹175.92 Crore. Arinna is a specialist in the CNS therapeutic segment with a dedicated field force. This acquisition allows Rubicon to leverage its IP and chronic products portfolio while gaining access to Arinna’s established Indian sales and distribution network.
Rubicon Research Limited entered into definitive agreements to acquire an 85% stake in Arinna Lifesciences Limited for approximately ₹175.92 Crore. Arinna, a CNS-focused pharmaceutical marketing company with ₹71.5 Crore FY25 turnover, will become a subsidiary. The acquisition strengthens Rubicon's Indian market presence and distribution network for specialty products.